Similar articles

• Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

  Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS. Vredenburgh JJ, et al. J Clin Oncol. 2007 Oct 20;25(30):4722-9. doi: 10.1200/JCO.2007.12.2440. J Clin Oncol. 2007. PMID: 17947719 Clinical Trial.
• Bevacizumab: a treatment option for recurrent glioblastoma multiforme.

  Buie LW, Valgus J. Buie LW, et al. Ann Pharmacother. 2008 Oct;42(10):1486-90. doi: 10.1345/aph.1L030. Epub 2008 Sep 2. Ann Pharmacother. 2008. PMID: 18765835 Review.
• A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme.

  Zhang G, Huang S, Wang Z. Zhang G, et al. J Clin Neurosci. 2012 Dec;19(12):1636-40. doi: 10.1016/j.jocn.2011.12.028. Epub 2012 Oct 6. J Clin Neurosci. 2012. PMID: 23047061
• Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.

  Hofland KF, Hansen S, Sorensen M, Engelholm S, Schultz HP, Muhic A, Grunnet K, Ask A, Costa JC, Kristiansen C, Thomsen C, Poulsen HS, Lassen U. Hofland KF, et al. Acta Oncol. 2014 Jul;53(7):939-44. doi: 10.3109/0284186X.2013.879607. Epub 2014 Jan 23. Acta Oncol. 2014. PMID: 24456504 Clinical Trial.
• Irinotecan and bevacizumab in recurrent glioblastoma multiforme.

  Jakobsen JN, Hasselbalch B, Stockhausen MT, Lassen U, Poulsen HS. Jakobsen JN, et al. Expert Opin Pharmacother. 2011 Apr;12(5):825-33. doi: 10.1517/14656566.2011.566558. Epub 2011 Mar 9. Expert Opin Pharmacother. 2011. PMID: 21385110 Review.